Association study of TRAF1/C5 polymorphism (rs10818488) with susceptibility to rheumatoid arthritis and systemic lupus erythematosus: A meta-analysis

Gene

Volumn 517, Issue 1, 2013, Pages 46-54

  Xu, Ke ^a   Peng, Hui ^a   Zhou, Mo ^a   Wang, Wei ^a   Li, Rui ^a   Zhu, Kao Kao ^a   Zhang, Min ^a   Wen, Peng Fei ^a   Pan, Hai Feng ^a   Ye, Dong Qing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; Polymorphism; Rheumatoid arthritis; Systemic lupus erythematosus; Tumor necrosis factor receptor associated factor 1

Indexed keywords

COMPLEMENT COMPONENT C5; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA POLYMORPHISM; EUROPE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NORTH AFRICA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

ARTHRITIS, RHEUMATOID; COMPLEMENT C5; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; POLYMORPHISM, GENETIC; TNF RECEPTOR-ASSOCIATED FACTOR 1;

EID: 84873526611     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.12.092     Document Type: Article

References (40)

1. Alarcón-Segovia D., et al. Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum. 2005, 52:1138-1147.
2. Allegretti M., et al. Targeting C5a: recent advances in drug discovery. Curr. Med. Chem. 2005, 12:217-236.
3. Bao L., Quigg R.J. Complement in lupus nephritis: the good, the bad, and the unknown. Semin. Nephrol. 2007, 27:69-80.
4. Barton A., et al. Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. Hum. Mol. Genet. 2008, 17:2274-2279.
5. Bland M. Meta-analysis: Dealing with Heterogeneity 2006, University of York, York.
6. Bowes J., Barton A. Recent advances in the genetics of RA susceptibility. Rheumatology (Oxford) 2008, 47:399-402.
7. Cornélis F., et al. New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:10746-10750.
8. Daha N.A., et al. Confirmation of STAT4, IL2/IL21, and CTLA4 polymorphisms in rheumatoid arthritis. Arthritis Rheum. 2009, 60:1255-1260.
9. Davidson A., Diamond B. Autoimmune diseases. N. Engl. J. Med. 2001, 345:340-350.
10. Deapen D., et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 1992, 35:311-318.
11. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7:177-188.
12. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
13. El-Gabalawy H.S., et al. Non-HLA genes modulate the risk of rheumatoid arthritis associated with HLA-DRB1 in a susceptible North American Native population. Genes Immun. 2011, 12:568-574.
14. Fakhfakh Karray E., Chalbi H., Ben Dhifallah I., Zakraoui L., Hamzaoui K. Association study of TRAF1-C5 polymorphism with susceptibility to rheumatoid arthritis in Tunisian population. Joint Bone Spine 2012, 79:331-332.
15. Graham R.R., et al. Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. Eur. J. Hum. Genet. 2007, 15:823-830.
16. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21:1539-1558.
17. Kurreeman F.A., et al. A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis. PLoS Med. 2007, 4:e278.
18. Kurreeman F.A., et al. The TRAF1-C5 region on chromosome 9q33 is associated with multiple autoimmune diseases. Ann. Rheum. Dis. 2010, 69:696-699.
19. MacGregor A.J., et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 2000, 43:30-37.
20. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959, 22:719-748.
21. Marrack P., Kappler J., Kotzin B.L. Autoimmune disease: why and where it occurs. Nat. Med. 2001, 7:899-905.
22. Mohamed R.H., Pasha H.F., El-Shahawy E.E. Influence of TRAF1/C5 and STAT4 genes polymorphisms on susceptibility and severity of rheumatoid arthritis in Egyptian population. Cell. Immunol. 2012, 273:67-72.
23. Nishimoto K., et al. Association study of TRAF1-C5 polymorphisms with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese. Ann. Rheum. Dis. 2010, 69:368-373.
24. Osorio Y., et al. Dense genome-wide linkage analysis of rheumatoid arthritis, including covariates. Arthritis Rheum. 2004, 50:2757-2765.
25. Palomino-Morales R.J., et al. STAT4 but not TRAF1/C5 variants influence the risk of developing rheumatoid arthritis and systemic lupus erythematosus in Colombians. Genes Immun. 2008, 9:379-382.
26. Pan H.F., Ye D.Q., Li X.P. Type 17T-helper cells might be a promising therapeutic target for systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 2008, 4:352-353.
27. Patsopoulos N.A., Ioannidis J.P. Susceptibility variants for rheumatoid arthritis in the TRAF1-C5 and 6q23 loci: a meta-analysis. Ann. Rheum. Dis. 2010, 69:561-566.
28. Perdigones N., et al. 6q23 polymorphisms in rheumatoid arthritis Spanish patients. Rheumatology (Oxford) 2009, 48:618-621.
29. Petitti D.B. Meta-analysis, Decision Analysis, and Cost-effectiveness Analysis 1994, Oxford University Press, New York.
30. Plenge R.M., et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am. J. Hum. Genet. 2005, 77:1044-1060.
31. Plenge R.M., et al. TRAF1-C5 as a risk locus for rheumatoid arthritis-a genomewide study. N. Engl. J. Med. 2007, 357:1199-1209.
32. Sabbagh L., et al. A critical role for TNF receptor-associated factor 1 and Bim down-regulation in CD8 memory T cell survival. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:18703-18708.
33. Sánchez E., et al. Identification of novel genetic susceptibility loci in African American lupus patients in a candidate gene association study. Arthritis Rheum. 2011, 63:3493-3501.
34. Tsitsikov E.N., et al. TRAF1 is a negative regulator of TNF signaling. enhanced TNF signaling in TRAF1-deficient mice. Immunity 2001, 15:647-657.
35. Wajant H., Henkler F., Scheurich P. The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. Cell. Signal. 2001, 13:389-400.
36. Wandstrat A., Wakeland E. The genetics of complex autoimmune diseases: non-MHC susceptibility genes. Nat. Immunol. 2001, 2:802-809.
37. Wellcome Trust Case Control Consortium Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-678.
38. Yang W., et al. Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. PLoS Genet. 2010, 6:e1000841.
39. Zervou M.I., et al. Association of a TRAF1 and a STAT4 gene polymorphism with increased risk for rheumatoid arthritis in a genetically homogeneous population. Hum. Immunol. 2008, 69:567-571.
40. Zervou M.I., et al. TRAF1/C5, eNOS, C1q, but not STAT4 and PTPN22 gene polymorphisms are associated with genetic susceptibility to systemic lupus erythematosus in Turkey. Hum. Immunol. 2011, 72:1210-1213.